Trotter J L, van der Veen R C, Clifford D B
Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110.
J Neuroimmunol. 1990 Jun;28(1):9-14. doi: 10.1016/0165-5728(90)90036-m.
Serum levels of immunoreactive interleukin-2 (IL-2) were determined at monthly intervals from a group of placebo- and drug-treated chronic progressive multiple sclerosis patients before and during a cyclosporine A therapeutic trial. Significantly elevated levels of the lymphokine in active patients confirmed earlier studies. The magnitude of the initial levels varied inversely with the duration of disease and predicted subsequent worsening in chronic progressive patients. In addition, the occurrence of periodic bursts of serum IL-2 was noted. Although in some patients there appeared to be a sudden drop in serum IL-2 levels with the onset of cyclosporine A medication, no effect of this drug was noted on group analysis.
在一项环孢素A治疗试验之前及期间，每月对一组接受安慰剂和药物治疗的慢性进行性多发性硬化症患者测定血清免疫反应性白细胞介素-2（IL-2）水平。活动期患者体内淋巴因子水平显著升高，证实了早期研究结果。初始水平的高低与疾病持续时间呈负相关，并可预测慢性进行性患者病情的后续恶化。此外，还观察到血清IL-2出现周期性爆发。虽然在一些患者中，环孢素A用药开始后血清IL-2水平似乎突然下降，但在组间分析中未发现该药物有任何作用。
